STR 324

Drug Profile

STR 324

Alternative Names: STR-324

Latest Information Update: 14 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Institut Pasteur
  • Developer Institut Pasteur; Stragen Pharma SA
  • Class Analgesics; Peptides
  • Mechanism of Action Neprilysin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 20 Feb 2018 Phase-I clinical trials in Pain (In volunteers) in Netherlands (IV) (NCT03430232)
  • 12 Feb 2018 Stragen plans a phase I trial for Pain in Netherlands in February 2018(NCT03430232) (EudraCT2014-002402-21)
  • 01 May 2017 Stragen plans a proof-of-concept trial for Pain in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top